Lortalamine (LM-1404) is an antidepressant which was synthesized in the early 1980s.[1][2] It acts as a potent and highly selective norepinephrine reuptake inhibitor.[3][4] Lortalamine was under development for clinical use but was shelved, likely due to the finding that it produced ocular toxicity in animals.[5][6] It has been used to label the norepinephrine transporter in positron emission tomography studies.[4][7][8]
[edit] See also
[edit] References
- ^ David J. Triggle (1997). Dictionary of pharmacological agents. London: Chapman & Hall. ISBN 0-412-46630-9. http://books.google.com/books?id=A0THacd46ZsC&lpg=PA1235&dq=lortalamine&pg=PA1235#v=onepage&q=lortalamine&f=false.
- ^ Belleville M, Grand M, Briet P (1981). "Plasma levels, elimination and metabolic fate of 4a-amino-8-chloro-2-methyl-1,2,3,4,4a,10a-hexahydro-10H-benzopyrano[3,2-cpyridin-10-ylacetic acid lactam, a new antidepressive agent, in rats and dogs"]. Drug Metabolism and Disposition: the Biological Fate of Chemicals 9 (3): 233–9. PMID 6113932. http://dmd.aspetjournals.org/cgi/pmidlookup?view=long&pmid=6113932.
- ^ Depin JC, Betbeder-Matibet A, Bonhomme Y, Muller AJ, Berthelon JJ (1985). "Pharmacology of lortalamine, a new potent non-tricyclic antidepressant". Arzneimittel-Forschung 35 (11): 1655–62. PMID 4091869.
- ^ a b Lin KS, Ding YS (August 2005). "Synthesis and C-11 labeling of three potent norepinephrine transporter selective ligands ((R)-nisoxetine, lortalamine, and oxaprotiline) for comparative PET studies in baboons". Bioorganic & Medicinal Chemistry 13 (15): 4658–66. doi:10.1016/j.bmc.2005.04.062. PMID 15914010. http://linkinghub.elsevier.com/retrieve/pii/S0968-0896(05)00372-X.
- ^ Elsom LF, Biggs SR, Chasseaud LF, Hawkins DR, Pulsford J, Darragh A (1985). "Metabolism of the anti-depressant lortalamine". European Journal of Drug Metabolism and Pharmacokinetics 10 (3): 209–15. PMID 4085522.
- ^ Mally C, Thiebault JJ (1990). "Ocular toxicity in beagle dogs with lortalamine, a non tricyclic antidepressant compound". Drug and Chemical Toxicology 13 (4): 309–23. doi:10.3109/01480549009032289. PMID 2279460. http://informahealthcare.com/doi/abs/10.3109/01480549009032289.
- ^ Ding YS, Lin KS, Logan J, Benveniste H, Carter P (July 2005). "Comparative evaluation of positron emission tomography radiotracers for imaging the norepinephrine transporter: (S,S) and (R,R) enantiomers of reboxetine analogs ([11Cmethylreboxetine, 3-Cl-[11C]methylreboxetine and [18F]fluororeboxetine), (R)-[11C]nisoxetine, [11C]oxaprotiline and [11C]lortalamine"]. Journal of Neurochemistry 94 (2): 337–51. doi:10.1111/j.1471-4159.2005.03202.x. PMID 15998285. http://www3.interscience.wiley.com/resolve/openurl?genre=article&sid=nlm:pubmed&issn=0022-3042&date=2005&volume=94&issue=2&spage=337.
- ^ Ding YS, Lin KS, Logan J (2006). "PET imaging of norepinephrine transporters". Current Pharmaceutical Design 12 (30): 3831–45. PMID 17073682.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Serotonin modulators and stimulators (SMSs)
|
|
|
|
Others
|
|
|
|
|
|
|
|
|
|
|
|
Nonselective
|
|
|
|
MAOA-Selective
|
|
|
|
MAOB-Selective
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
* Note that MAO-B inhibitors also influence norepinephrine/epinephrine levels since they inhibit the breakdown of their precursor dopamine.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
